

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**23rd March 2020**Clarification and Update on COVID-19 Testing**

Further to the release of Zoono Group Limited (Company) (ASX: ZNO) made on the 28th February regarding successful testing against COVID-19 the company wishes to clarify the testing of Zoono Z-71 Microbe Shield was conducted on the COVID-19 Surrogate known as the Feline Coronavirus not the COVID-19 virus itself, the surrogate used is an accepted surrogate for COVID-19 and is tested in laboratories globally for this purpose.

Zoono is pleased to advise that the Companies hand sanitiser has now also been tested against the COVID-19 surrogate Feline Coronavirus and has shown to be effective at >99.99%.

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:**Zoono Group Limited**

Paul Hyslop

Managing Director/CEO

M: +64 21 659977

E: paul.hyslop@zoono.com.

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com